Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05659576 · ClinicalTrials.gov registry record · Phase 2
Reducing Acute Upper Gastrointestinal Side-Effects of Thoracic Irradiation
A Phase 2 study of Radiation Esophagitis, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
- 7
- Study locations
NCT05659576: Active Phase 2 study of Radiation Esophagitis, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05659576 is a Phase 2 study of Radiation Esophagitis that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 142 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05659576, a Phase 2 study of Radiation Esophagitis, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of the study is to explore options for preventing and reducing symptoms of radiation esophagitis (RE). The researchers will also look what symptoms participants experience, and whether there are differences in weight loss in participants.
Primary Outcome
Determine accrual rate of two-stage consent compared to standard onestage consent.
Conditions Studied
Interventions
- OTHER Usual Care
- DRUG Sucralfate
- OTHER One consent
- OTHER Two consent
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities ) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Cancer Center Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2022-12-13 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT05659576 still lists
NCT05659576 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Radiation Esophagitis appearing as the primary indexed condition, and to 4 interventions - of which Usual Care is the first listed.
NCT05659576 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT05659576 about?
NCT05659576 is a clinical study titled "Reducing Acute Upper Gastrointestinal Side-Effects of Thoracic Irradiation". The purpose of the study is to explore options for preventing and reducing symptoms of radiation esophagitis (RE). The researchers will also look what symptoms participants experience, and whether there are differences in weight loss in participants.
What is the current status of trial NCT05659576?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2022-12-13. Estimated completion is 2026-12.
What conditions does trial NCT05659576 study?
This clinical trial studies the following conditions: Radiation Esophagitis.
What interventions are being tested in trial NCT05659576?
The interventions under investigation include: Usual Care (OTHER), Sucralfate (DRUG), One consent (OTHER), Two consent (OTHER).
Who is sponsoring clinical trial NCT05659576?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05659576 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Radiation Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05659576's enrollment target sits among peer trials
142 507th of 2000 higher than 1,491 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI